This down draft in KPTI appears to be a great entry point. AML have a high incident for sepsis in the first place. The 8 patients who did get sepsis could be in the normal range. Changing dosage in clinical trial is pretty typical.
Fluidigm weakness a buying opportunity, says Leerink
Mizuho maintains neutral rating but Fluidigm price target lowered to $15
TNET has a low float and is also thinly traded (typically). This contributed to the exaggerated move at the open.
TriNet shares to be down more than 15%, says JPMorgan (no s##t)
JPMorgan expects shares of TriNet to be down more than the 2015 EBITDA guidance cut of 15% given management credibility concerns following the company's Q2 miss. It lowered its price target for shares to $24 from $39 but keeps an Overweight rating on the stock. TriNet continues to post solid underlying unit growth, JPMorgan points out.
With a Forward P/E now at 15.17 and PEG Ratio at 1.00, SWI is now at a very attractive entry point. The low daily volume explains the exaggerated move this morning.
Also, SWI is trading 20-30% below NEW target prices.
I almost pulled the trigger last night in AH around 42. Glad I waited.
I wonder if other brokers besides Fidelity are allowing. I would think volume should be even higher than it is.
ZUMZ is a stock that many love to hate. In the past, me included. I have stayed away from ZUMZ for a while. Revisiting it now, It is pretty surprising how its PE, Foward PE, PEG are now in line with real businesses and their PPS.
PE in the 16s, Forward PE in the 11s ?? ZUMZ looks attractively priced to me. I bought at 25, so I am a little underwater at current price 24.11. But I think that is still a decent price once the day traders get done with this.